Akili, Inc. (Nasdaq: AKLI), the Boston-based prescription digital therapeutics company, has announced it will cut 30% of its workforce in an effort to extend its financial runway. The move will impact 46 employees and is scheduled to be completed by the end of the first quarter. At the end of September 2022, Akili employed 143 staff members, according to its third-quarter financial filings. The decision comes after approval from Akili’s board of directors on Jan. 11 and was communicated to employees the following day. Alongside the layoffs, the company is reprioritizing its development pipeline, focusing resources on its most commercially viable products. CEO Eddie Martucci stated, “As difficult as this decision is, it is the right thing to do for our business and all Akili shareholders, and, most importantly, we believe it best enables us to deliver on our promise to millions of patients.” These Akili layoffs digital therapeutics reflect the company’s effort to navigate an evolving financial environment.
Financial Pressures and Market Challenges
Akili went public in August 2022 via a SPAC merger, raising $163 million. Although the stock initially surged to $37.58, it has since dropped dramatically to $1.39 — a decline of 96%. This steep reduction in market value emphasizes the challenges facing Akili as it attempts to establish its presence in the prescription digital therapeutics sector.
Despite FDA clearance for its flagship product EndeavorRx, designed to treat pediatric ADHD, Akili has yet to generate significant revenue. Through the third quarter of 2022, the company reported just $212,000 in total revenue while incurring $68.6 million in operating expenses. These financial pressures played a major role in the recent Akili layoffs digital therapeutics.
Prescription Digital Therapeutics: Growing Pains
Akili is a pioneer in prescription digital therapeutics, with EndeavorRx being the first FDA-cleared video game-based therapy for pediatric ADHD. Its pipeline also includes potential treatments for adult ADHD and autism spectrum disorder. However, the sector faces hurdles as payers and regulators are still evaluating reimbursement models for these novel therapies. Companies like Akili must balance innovation with commercial sustainability, and the recent Akili layoffs digital therapeutics highlight the difficulty of this challenge.
Extending the Cash Runway
The layoffs are expected to cost Akili between $1.5 million and $2.5 million, but they will provide roughly six months of additional cash runway. The company reported $89.7 million in cash reserves, which was originally expected to fund operations until mid-2024. Following the cost-cutting measures, Akili now projects its runway will extend through the first quarter of 2025. Operating expenses for 2023 are projected between $55 million and $60 million, reflecting a leaner and more strategic approach.
Martucci acknowledged the personal weight of the decision, saying, “I take personal and sole responsibility for how we have grown, and for being in a position where instilling more operational efficiency means a reduction of employees and roles.” These Akili layoffs digital therapeutics were a difficult but necessary choice to preserve the company’s ability to innovate and deliver patient solutions.
Industry Implications
The news of Akili layoffs digital therapeutics underscores broader challenges in the digital health and behavioral technology space. While clinical innovation continues at a rapid pace, achieving commercial success and sustainable revenue remains challenging. Investors and payers are increasingly focused on operational efficiency and financial stability, forcing companies like Akili to adjust their strategies.
In conclusion, these Akili layoffs digital therapeutics reflect the delicate balance digital health companies must maintain between innovation, market adoption, and financial sustainability. By streamlining operations, Akili hopes to position itself for long-term success while continuing to advance its pioneering treatments for ADHD and other neurobehavioral conditions.
